Employment AgreementEmployment Agreement • June 22nd, 2018 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (the “Agreement”) is made and entered into as of September , 2015 by and between Philip Astley-Sparke (the “Executive”) and Replimune, Inc., a Delaware Corporation (the “Company”).
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTClinical Trial Collaboration and Supply Agreement • June 22nd, 2018 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Delaware
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (the “Agreement”) is made and entered into effective as of the date signed by the last Party to sign below (the “Effective Date”) by and between Replimune Inc., a corporation organized under the laws of Delaware, having a place of business at 18 Commerce Way, Woburn, MA 01801 (the “Recipient”) and Bristol-Myers Squibb Company, having a place of business at 345 Park Avenue, New York, NY 10154 (“BMS”). The Recipient and BMS are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”
33 NEW YORK AVENUE FRAMINGHAM, MASSACHUSETTS 01701 LEASE SUMMARY SHEETIndenture of Lease • June 22nd, 2018 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS INDENTURE OF LEASE (this “Lease”) is hereby made and entered into on the Execution Date by and between Landlord and Tenant.
n I. D 0 0 D 0 0 D 0 D D 0 D Lr Atvtl Dated 2016 Lease between MEPC Milton Park No.1 Limited and MEPC Milton Park No. 2 Limited and Replimune Limited relating to 69 and 70 Innovation Drive Milton Park u ""1 J mmmm II MiltonPark :fi1 BrookStreet des...Replimune Group, Inc. • June 22nd, 2018 • Biological products, (no disgnostic substances)
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • June 22nd, 2018 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 21 day of July, 2017, by and among Replimune Group, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A (the “Investors”) and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder”.
